Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1437 | 761 | 100.0% | 379 | major |
GlaxoSmithKline | 1133 | 500 | 100.0% | 488 | major |
Pfizer | 844 | 258 | 98.4% | 441 | major |
Merck Sharp & Dohme (MSD) | 781 | 434 | 99.8% | 173 | major |
Roche | 712 | 195 | 92.3% | 289 | major |
Sanofi S.A. | 680 | 179 | 99.4% | 391 | major |
Astrazeneca | 656 | 244 | 96.3% | 204 | major |
Johnson & Johnson | 513 | 177 | 98.9% | 207 | major |
Eli Lilly | 445 | 154 | 99.4% | 168 | major |
Medical University of Vienna | 401 | 220 | 26.8% | 36 | major |
Bristol-Myers Squibb | 378 | 88 | 96.6% | 153 | major |
Boehringer Ingelheim | 374 | 149 | 100.0% | 155 | major |
Bayer | 319 | 207 | 100.0% | 56 | major |
Hospitals of Paris (AP-HP) | 307 | 28 | 3.6% | 46 | major |
Amgen Inc | 285 | 92 | 98.9% | 124 | major |
Novo Nordisk | 246 | 92 | 100.0% | 98 | major |
Gilead Sciences Inc | 242 | 101 | 99.0% | 97 | major |
KU Leuven | 242 | 32 | 78.1% | 28 | major |
Abbvie | 235 | 98 | 98.0% | 41 | major |
Rigshospitalet | 231 | 90 | 18.9% | 49 | major |
Radboud University | 227 | 26 | 42.3% | 36 | major |
Karolinska Institutet | 220 | 26 | 11.5% | 23 | major |
UCB | 214 | 65 | 93.8% | 103 | major |
No Sponsor Name Given | 212 | 44 | 40.9% | 33 | major |
Takeda | 209 | 89 | 98.9% | 62 | major |
Erasmus University | 205 | 5 | 20.0% | 28 | major |
Charité-Universitätsmedizin Berlin | 197 | 75 | 56.0% | 35 | major |
University of Amsterdam | 189 | 13 | 0.0% | 29 | major |
Aarhus University | 187 | 78 | 46.2% | 21 | major |
Merck KGaA | 171 | 48 | 97.9% | 74 | major |
VU University Medical Centre | 168 | 15 | 0.0% | 18 | major |
University College London | 162 | 82 | 93.9% | 7 | major |
Leiden University | 158 | 9 | 11.1% | 14 | major |
Astellas | 152 | 46 | 100.0% | 75 | major |
Agostino Gemelli University Polyclinic | 150 | 11 | 0.0% | 102 | major |
University of Groningen | 150 | 6 | 0.0% | 9 | major |
Utrecht University | 149 | 16 | 18.8% | 40 | major |
University of Oxford | 146 | 76 | 82.9% | 5 | major |
Imperial College London | 144 | 95 | 96.8% | 6 | major |
Servier Laboratories | 144 | 66 | 100.0% | 52 | major |
Allergan | 142 | 72 | 95.8% | 36 | major |
Ghent University | 142 | 39 | 20.5% | 46 | major |
Celgene | 138 | 42 | 92.9% | 37 | major |
Novartis Vaccines | 132 | 56 | 100.0% | 67 | major |
AOU di Bologna, Policlinico S.Orsola-Malpighi | 127 | 1 | 0.0% | 33 | major |
Eisai Inc. | 125 | 37 | 97.3% | 61 | major |
IRCCS Ospedale San Raffaele | 124 | 7 | 28.6% | 48 | major |
Biogen | 123 | 59 | 96.6% | 39 | major |
Medical University of Graz | 122 | 64 | 45.3% | 8 | major |
Helsinki University | 120 | 18 | 22.2% | 9 | major |
Pierre Fabre S.A. | 118 | 68 | 98.5% | 22 | major |
University of Birmingham | 118 | 50 | 92.0% | 4 | major |
Shire | 111 | 32 | 100.0% | 54 | major |
Abbott | 109 | 73 | 95.9% | 31 | major |
Odense University Hospital | 108 | 45 | 31.1% | 21 | major |
Chiesi Farmaceutici S.p.A | 107 | 54 | 100.0% | 32 | major |
University of Oslo | 107 | 6 | 16.7% | 9 | major |
King’s College London | 106 | 68 | 97.1% | 2 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 105 | 28 | 78.6% | 34 | major |
Hospices Civils de Lyon | 104 | 14 | 0.0% | 9 | major |
Vertex Pharmaceuticals, Inc. | 99 | 41 | 100.0% | 34 | major |
Université libre de Bruxelles | 96 | 7 | 0.0% | 12 | major |
Teva | 95 | 47 | 91.5% | 36 | major |
Actelion Pharmaceuticals Ltd | 95 | 32 | 100.0% | 38 | major |
Ipsen | 89 | 39 | 100.0% | 33 | major |
Herlev and Gentofte Hospital | 89 | 37 | 56.8% | 15 | major |
H. Lundbeck A/S | 86 | 42 | 97.6% | 30 | major |
CSL Behring | 85 | 34 | 100.0% | 39 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 46 | 100.0% | 2 | major |
Unicancer | 82 | 5 | 0.0% | 3 | major |
National Cancer Institute Italy | 79 | 3 | 0.0% | 18 | major |
Genentech | 78 | 39 | 100.0% | 19 | major |
Antoni van Leeuwenhoek Hospital | 78 | 2 | 0.0% | 8 | major |
Fundació Clínic per a la Recerca Biomèdica | 77 | 5 | 0.0% | 29 | major |
University of Munich (Ludwig-Maximilians) | 76 | 37 | 13.5% | 5 | major |
Alcon | 76 | 36 | 100.0% | 39 | major |
Daiichi Sankyo | 76 | 28 | 100.0% | 29 | major |
Gothenburg University | 75 | 7 | 14.3% | 11 | major |
University of Dundee | 74 | 68 | 98.5% | 1 | major |
Otsuka | 74 | 38 | 92.1% | 24 | major |
Regeneron Pharmaceuticals Inc. | 74 | 14 | 100.0% | 21 | major |
University of Cologne | 73 | 31 | 77.4% | 8 | major |
Maastricht University | 73 | 6 | 0.0% | 14 | major |
University of Leeds | 72 | 50 | 100.0% | 1 | major |
NHS Greater Glasgow and Clyde | 71 | 36 | 75.0% | 4 | major |
Innsbruck Medical University | 70 | 26 | 73.1% | 7 | major |
Incyte Corporation | 70 | 15 | 80.0% | 10 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 53 | 90.6% | 1 | major |
Menarini Group | 69 | 43 | 93.0% | 12 | major |
Alexion Pharmaceuticals, Inc | 69 | 20 | 85.0% | 21 | major |
CHU de Toulouse | 69 | 12 | 0.0% | 10 | major |
Technical University of Munich | 67 | 32 | 87.5% | 11 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 66 | 41 | 82.9% | 3 | major |
Manchester University NHS Foundation Trust | 64 | 53 | 100.0% | 0 | major |
Queen Mary University of London | 64 | 37 | 100.0% | 3 | major |
Vrije Universiteit Brussel | 64 | 4 | 25.0% | 9 | major |
University of Nottingham | 63 | 54 | 94.4% | 4 | major |
Baxter | 63 | 47 | 93.6% | 9 | major |
Vall d'Hebron University Hospital | 63 | 4 | 0.0% | 12 | major |
Galderma R&D | 62 | 34 | 97.1% | 14 | major |
CHU Clermont-Ferrand | 62 | 10 | 0.0% | 7 | major |
Hospital de la Santa Creu i Sant Pau | 61 | 10 | 0.0% | 13 | major |
Heidelberg University Hospital | 60 | 27 | 63.0% | 5 | major |
University Hospital Tübingen | 60 | 17 | 17.6% | 8 | major |
Almirall S.A. | 59 | 39 | 100.0% | 10 | major |
LEO Pharma A/S | 59 | 32 | 96.9% | 14 | major |
The Royal Marsden NHS Foundation Trust | 59 | 27 | 81.5% | 2 | major |
Bispebjerg Hospital | 58 | 31 | 32.3% | 9 | major |
European Institute of Oncology | 58 | 1 | 0.0% | 16 | major |
Ferring Pharmaceuticals | 57 | 29 | 96.6% | 20 | major |
University of Turku | 57 | 11 | 18.2% | 3 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 95.6% | 5 | major |
University Erlangen-Nuremberg | 56 | 23 | 60.9% | 3 | major |
Cliniques Universitaires Saint-Luc | 56 | 4 | 0.0% | 12 | major |
HOVON Foundation | 56 | 2 | 0.0% | 3 | major |
Belfast Health and Social Care Trust | 55 | 43 | 81.4% | 1 | major |
CHU de Bordeaux | 54 | 9 | 0.0% | 10 | major |
Mundipharma | 53 | 30 | 90.0% | 15 | major |
Hannover Medical School | 53 | 29 | 20.7% | 13 | major |
King's College Hospital NHS Foundation Trust | 52 | 37 | 94.6% | 1 | major |
Hvidovre Hospital | 52 | 19 | 26.3% | 12 | major |
Skåne University Hospital | 52 | 10 | 20.0% | 4 | major |
Barts Health NHS Trust | 51 | 42 | 97.6% | 4 | major |
Cambridge University Hospitals NHS Foundation Trust | 51 | 36 | 91.7% | 5 | major |
BioMarin Pharmaceutical Inc | 51 | 19 | 78.9% | 13 | major |
University Hospital Southampton NHS Foundation Trust | 51 | 19 | 21.1% | 2 | major |
Policlinico San Matteo | 51 | 4 | 0.0% | 32 | major |
Johannes Gutenberg University of Mainz | 50 | 29 | 44.8% | 7 | major |
University of Hamburg | 50 | 16 | 43.8% | 6 | major |